Becton, Dickinson and Company (NYSE:BDX) Shares Acquired by Douglass Winthrop Advisors LLC

Douglass Winthrop Advisors LLC lifted its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 3.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 423,738 shares of the medical instruments supplier's stock after purchasing an additional 13,520 shares during the quarter. Becton, Dickinson and Company comprises about 1.9% of Douglass Winthrop Advisors LLC's holdings, making the stock its 22nd largest holding. Douglass Winthrop Advisors LLC owned 0.15% of Becton, Dickinson and Company worth $96,133,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in BDX. Charles Schwab Investment Management Inc. raised its holdings in shares of Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier's stock worth $720,089,000 after acquiring an additional 1,317,723 shares during the period. First Eagle Investment Management LLC raised its stake in Becton, Dickinson and Company by 31.4% during the fourth quarter. First Eagle Investment Management LLC now owns 4,426,022 shares of the medical instruments supplier's stock worth $1,004,132,000 after purchasing an additional 1,057,879 shares during the period. Raymond James Financial Inc. acquired a new position in Becton, Dickinson and Company in the 4th quarter valued at about $181,279,000. Nordea Investment Management AB grew its stake in shares of Becton, Dickinson and Company by 31.0% in the 4th quarter. Nordea Investment Management AB now owns 2,844,566 shares of the medical instruments supplier's stock valued at $647,082,000 after buying an additional 673,568 shares during the period. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Becton, Dickinson and Company by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier's stock worth $1,293,635,000 after buying an additional 460,440 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company's stock.

Remove Ads

Becton, Dickinson and Company Trading Down 0.5 %

BDX traded down $1.23 during mid-day trading on Tuesday, hitting $227.96. 1,675,001 shares of the stock were exchanged, compared to its average volume of 1,535,323. The firm's fifty day moving average is $232.43 and its two-hundred day moving average is $231.91. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99. The company has a market cap of $65.46 billion, a PE ratio of 37.87, a PEG ratio of 1.63 and a beta of 0.35. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a dividend yield of 1.82%. Becton, Dickinson and Company's dividend payout ratio (DPR) is 69.10%.

Becton, Dickinson and Company announced that its board has initiated a stock buyback program on Tuesday, January 28th that permits the company to buyback 10,000,000 shares. This buyback authorization permits the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares buyback programs are generally an indication that the company's management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. StockNews.com upgraded Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a report on Wednesday, March 5th. Barclays upped their price target on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. Finally, Piper Sandler raised their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an "overweight" rating in a research report on Tuesday, January 28th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average price target of $278.29.

Insider Transactions at Becton, Dickinson and Company

In other news, Director Jeffrey William Henderson bought 1,500 shares of the business's stock in a transaction that occurred on Monday, February 10th. The shares were purchased at an average cost of $233.62 per share, for a total transaction of $350,430.00. Following the completion of the purchase, the director now owns 8,015 shares of the company's stock, valued at approximately $1,872,464.30. This represents a 23.02 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Richard Byrd sold 1,940 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $224.91, for a total transaction of $436,325.40. Following the completion of the transaction, the executive vice president now owns 7,411 shares of the company's stock, valued at $1,666,808.01. This represents a 20.75 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,984 shares of company stock valued at $1,147,865. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.